presence or absence of treatment with IFNß-1a. The relationship between AUC-EDSS and time was defined by an equation of the type: In this equation, is the intercept common to all treatments and 1 ...

and meals to induce them to prescribe the MS drugs Avonex (interferon-beta-1a), Tysabri (natalizumab), and Tecfidera (dimethyl fumarate) between 2009 and 2014. That resulted in false claims for ...

This advertorial touches on Biogen’s role in disease management advances in the context of progress in MS. The pivotal clinical trial of Biogen’s intramuscular interferon beta-1a (IFN β-1a ...

Objective: To evaluate the cost effectiveness of subcutaneous interferon-ß-1a (IFNß-1a) 44µg three times weekly in relapsing-remitting multiple sclerosis (RRMS) using an econometric model.